Clinical Trials Logo

Filter by:
NCT ID: NCT00844662 Terminated - Clinical trials for Chronic Kidney Failure

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

Start date: July 2009
Phase: Phase 3
Study type: Interventional

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring haemodialysis, compared with a marketed phosphate binder, sevelamer hydrochloride.

NCT ID: NCT00840658 Completed - HIV Infections Clinical Trials

Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico

FSW-IDU
Start date: October 2008
Phase: Phase 2
Study type: Interventional

The investigators propose a highly efficient four-arm (factorial) trial to simultaneously test the efficacy of two behavioral interventions aimed at: - increasing condom use in the context of ongoing drug use and - decreasing needle and paraphernalia sharing among female sex workers who also inject drugs in two Mexican-U.S. border cities: Tijuana and Ciudad Juarez.

NCT ID: NCT00838903 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Start date: February 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.

NCT ID: NCT00838201 Completed - Prostate Cancer Clinical Trials

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Start date: February 1, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3 years under the 20040138 Amgen study and 2 years on this study) denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab for non-metastatic prostate cancer.

NCT ID: NCT00837811 Completed - Clinical trials for Rheumatoid Arthritis

An Open Label Extension Study in Participants With Rheumatoid Arthritis

Start date: February 2009
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability of LY2127399 administered as subcutaneous injections for 48 weeks in participants with Rheumatoid Arthritis

NCT ID: NCT00837499 Completed - Breast Cancer Clinical Trials

Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.

Start date: January 1, 2007
Phase:
Study type: Observational

The goal of this epidemiologic research study is to find out if various risk factors and certain markers (substances that help identify the presence of cancer) that help predict increased occurrence and prognosis (outcome of disease) of breast cancer differ among Mexican, Mexican-American, and African-American women.

NCT ID: NCT00836446 Completed - Obesity Clinical Trials

Effects of Physical Activity on Cardiovascular Risk Markers in School-Aged Mexican Children

Start date: August 2008
Phase: N/A
Study type: Interventional

Childhood obesity is a public health problem; in Mexican children a high prevalence of cardiovascular risk factors are present. Physical activity has been proposed as a strategy to reduce this risk. We conducted a pre-posttest intervention study of 214 school-aged Mexican children (4th to 6th grade), to assess the effects of two physical activity routines with different duration and intensity (40 minute aerobic routine vs. 20 minute routine) on cardiovascular risk markers. Physical activity routines were assigned randomly to two public schools in Toluca, Mexico (20 min: group 1 (n= 117), 40 min: group 2 (n=97)). The routines were implemented Monday through Friday for 12 weeks. Nutrition assessment was done before and after the intervention and included anthropometric measurements (weight, height, body mass index, waist circumference and body composition), blood pressure and biochemical analysis (triglycerides, total cholesterol LDL-cholesterol, HDL-Cholesterol, glucose and insulin). Heart rate was monitored 3 times during the intervention to evaluate the routine´s intensity.

NCT ID: NCT00835770 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

ENDORSE
Start date: February 3, 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.

NCT ID: NCT00833703 Completed - Clinical trials for Heart Defects, Congenital

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

CLARINET LT
Start date: January 2009
Phase: Phase 3
Study type: Interventional

This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt. The primary objective was to assess the safety up to 18 months of age of the extended use of Clopidogrel 0.2 mg/kg/day in patients for whom the shunt was still in place at one year of age. The secondary objective was to assess the efficacy on the occurrence of shunt thrombosis requiring intervention or any death.

NCT ID: NCT00832507 Terminated - Clinical trials for Pulmonary Arterial Hypertension

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

Start date: January 2009
Phase: Phase 2
Study type: Interventional

This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH. Study drug will be administered alone, or on the background of stable PAH therapy. The study will consist of 3 periods: a screening period, a 12-week placebo-controlled treatment period, and a long-term, blinded extension period.